FRISCO, Texas, April 27, 2017 /PRNewswire/ -- True Health Diagnostics today launched a new product that will help doctors provide patients with earlier-stage detection of hereditary cancers.
Primary care physicians can utilize True Health's genTrue™ hereditary cancer tests to identify individuals with suspected heritable cancer syndrome.
The creation of a hereditary cancer platform broadens True Health's already available early-detection and disease management programs for cardiovascular disease, diabetes, autoimmune disease and others. True Health's goal is to detect disease risk earlier than previously possible, then help patients and doctors develop programs to slow or defeat major diseases.
The genTrue™ hereditary cancer tests identify whether patients carry any of 26 different genes that increase the risk of developing breast, colon, prostate, ovarian, endometrial, gastric, melanoma or pancreatic cancer. Early intervention and proactive treatment could greatly improve patient outcomes.
To continue reading, click here >>
About True Health Diagnostics
True Health Diagnostics is a health services company providing innovative clinical services and diagnostic information to help people live longer, healthier lives. The company specializes in earlier-stage prevention and diagnosis of chronic disease, including cardiovascular, diabetes, cancer, genetic disorders and a range of metabolic conditions. True Health is a trusted partner of medical professionals because we help them obtain accurate and necessary diagnoses that can improve patient care. True Health is headquartered in Frisco, Texas, with operations across the country. More information can be found at truehealthdiag.com
News From Our Partners